USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$49.46B
Market Cap
36.95
P/E Ratio
2.28
EPS
$87.89
52 Week High
$65.94
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $4.3B |
| Total Revenue | $5.4B |
| Cost Of Revenue | $1.1B |
| Costof Goods And Services Sold | $1.1B |
| Operating Income | $1.4B |
| Selling General And Administrative | $1.8B |
| Research And Development | $1.1B |
| Operating Expenses | $2.9B |
| Investment Income Net | - |
| Net Interest Income | $101M |
| Interest Income | $120M |
| Interest Expense | $20M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $155M |
| Income Before Tax | $1.5B |
| Income Tax Expense | $152M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.4B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.6B |
| Ebitda | $1.7B |
| Net Income | $4.2B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $4.3B |
| Total Revenue | $5.4B |
| Cost Of Revenue | $1.1B |
| Costof Goods And Services Sold | $1.1B |
| Operating Income | $1.4B |
| Selling General And Administrative | $1.8B |
| Research And Development | $1.1B |
| Operating Expenses | $2.9B |
| Investment Income Net | - |
| Net Interest Income | $101M |
| Interest Income | $120M |
| Interest Expense | $20M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $155M |
| Income Before Tax | $1.5B |
| Income Tax Expense | $152M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.4B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.6B |
| Ebitda | $1.7B |
| Net Income | $4.2B |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Edwards Lifesciences Corp is a leading American medical technology company based in Irvine, California, specializing in innovative heart valve therapies and hemodynamic monitoring solutions. Renowned for its pioneering transcatheter heart valve technologies, Edwards is committed to improving clinical outcomes for patients suffering from heart diseases while enhancing their quality of life. With a robust portfolio and a strong pipeline of advanced products, the company is strategically positioned to shape the future of cardiac care, driving sustainable growth and long-term value within the healthcare sector.